Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Motoya

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Diseases of the Colon and Rectum|March 7, 2008
Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter surveyTakayuki Matsumoto, Mitsuo Iida, Satoshi Motoya, et al.
Crohn'S & Colitis 360|July 2, 2026
Long-term drug persistence and clinical outcomes of ustekinumab in Crohn's disease: a multicenter real-world study from the Hokkaido phoenix cohortTakahiro Ito, Atsuo Maemoto, Nobuhiro Ueno, et al.
Plos One|April 19, 2022
Correction: Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in JapanHitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, et al.
Inflammatory Bowel Diseases|April 3, 2009
Genetic variants in surfactant, pulmonary-associated protein D (SFTPD) and Japanese susceptibility to ulcerative colitisMichihiro Tanaka, Yoshiaki Arimura, Akira Goto, et al.
Intestinal Research|August 10, 2018
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studiesSatoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, et al.
Intestinal Research|May 11, 2018
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studiesSatoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, et al.
Journal of Gastroenterology|December 15, 2019
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analysesKenji Watanabe, Satoshi Motoya, Haruhiko Ogata, et al.
Journal of Gastroenterology|March 22, 2017
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Journal of Gastroenterology|December 29, 2004
Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective studyYoshihiro Fukuda, Toshiyuki Matsui, Yasuo Suzuki, et al.
Plos One|February 27, 2019
Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled studySatoshi Motoya, Kenji Watanabe, Haruhiko Ogata, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Diseases of the Colon and Rectum|March 7, 2008
Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter surveyTakayuki Matsumoto, Mitsuo Iida, Satoshi Motoya, et al.
Crohn'S & Colitis 360|July 2, 2026
Long-term drug persistence and clinical outcomes of ustekinumab in Crohn's disease: a multicenter real-world study from the Hokkaido phoenix cohortTakahiro Ito, Atsuo Maemoto, Nobuhiro Ueno, et al.
Plos One|April 19, 2022
Correction: Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in JapanHitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, et al.
Inflammatory Bowel Diseases|April 3, 2009
Genetic variants in surfactant, pulmonary-associated protein D (SFTPD) and Japanese susceptibility to ulcerative colitisMichihiro Tanaka, Yoshiaki Arimura, Akira Goto, et al.
Intestinal Research|August 10, 2018
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studiesSatoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, et al.
Intestinal Research|May 11, 2018
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studiesSatoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, et al.
Journal of Gastroenterology|December 15, 2019
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analysesKenji Watanabe, Satoshi Motoya, Haruhiko Ogata, et al.
Journal of Gastroenterology|March 22, 2017
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
Journal of Gastroenterology|December 29, 2004
Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective studyYoshihiro Fukuda, Toshiyuki Matsui, Yasuo Suzuki, et al.
Plos One|February 27, 2019
Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled studySatoshi Motoya, Kenji Watanabe, Haruhiko Ogata, et al.
Pageof 9